Navigation Links
Abingdon Life Sciences, Inc. Announces Opening of Office in Carlsbad, Ca.
Date:7/21/2008

CARLSBAD, Calif., July 21 /PRNewswire/ -- Abingdon Life Sciences announces the formal opening of its offices in Carlsbad, California. The offices, located at 5963 La Place Court, Suite 107, are in the Carlsbad Airport Business Park adjacent to Palomar Airport. Abingdon Life Sciences, Inc. is a first-in-class Drug, Device, Diagnostic Development Management Organization (DDMO), focused on providing drug and device companies with superior services based on an integrated strategic development model. An integrated development model focuses on the Target Product Profile (TPP) concept, and allows a platform to be assessed by key areas of opportunity and risk from both scientific and business aspects.

Abingdon was founded on the principle that a proactive strategic approach to development will yield better outcomes. Abingdon's philosophy is to provide clients with a focused approach to product development by building synergistic partnerships that use significant expertise to achieve the best outcome. Global core-competencies include pre-clinical, regulatory strategy and submissions, clinical development, biostatistics, report writing and post-marketing obligations. Abingdon provides services to clients with products initially filed under IND, CTX, 505(b)(2), NDA, ANDA, PMA and 510k applications. Abingdon's senior executives provide personalized oversight and leadership of projects to ensure the best possible customer experience. Key alliances enable Abingdon to assist with cGMP services from formulation development for clinical trial supply through commercialization.

"Abingdon's approach is to reduce the noise in the development process and provide objective direction that outlines the risks and benefits of the potential development pathways. In the end, our goal is to assist our clients to streamline their development process and help make decisions that will achieve their goals. We believe this will ultimately reduce costs to our clients and speed the time to market," stated Aidan Nuttall, Ph.D., President and C.O.O., Abingdon Life Sciences, Inc.

About Abingdon Life Sciences, Inc.:

Abingdon Life Sciences, Inc. is a first-in-class Drug and Device Development Management Organization (DDMO) providing drug and device companies superior clinical and regulatory services based on an integrated strategic development model. Abingdon's senior executives provide personalized oversight and leadership of projects to ensure the best possible customer experience.


'/>"/>
SOURCE Abingdon Life Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioTime, Inc. and Embryome Sciences, Inc. Sign Agreement With International Stem Cell Corporation to Provide Unique Human Stem Cell Lines for Research Use
2. Dow AgroSciences, Sangamo BioSciences Announce the Achievement of Key Milestones in Plant Agriculture Collaboration
3. Dow AgroSciences, Martek Biosciences Form Alliance to Bring Omega-3 Fatty Acids to Food Industry
4. Intellect Neurosciences, Inc. Grants License for Certain Patents and Patent Applications to Wyeth and Elan Pharma International Ltd.
5. Pressure BioSciences, Inc. to Discuss First Quarter 2008 Financial Results and Provide Business Update
6. RiverVest Venture Partners(R), a St. Louis-Based Venture Capital Firm Focusing on Life Sciences, Closes on Fund II, Names John P. McKearn, Ph.D., Venture Partner
7. Intellect Neurosciences, Inc. Receives Notice of Allowance and Completes Grant Requirements for Pivotal European Patent Related to Passive Immunization of Alzheimers Disease
8. Alimera Sciences, pSivida Limited Amend Medidur(TM) FA Collaboration Agreement
9. Matthew B. Potter Joins Pressure BioSciences, Inc. as Vice President of Sales
10. Pressure BioSciences, Inc. to Discuss 2007 Financial Results and Provide Business Update
11. DARA BioSciences, Inc. Announces Appointment of New Director to Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... , ... October 10, 2017 ... ... cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing ... HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s ...
(Date:10/10/2017)... International research firm Parks Associates announced today that ... TMA 2017 Annual Meeting , October 11 in Scottsdale, ... security market and how smart safety and security products impact the competitive ... Parks Associates: Smart Home Devices: Main ... "The residential security market has experienced continued ...
(Date:10/10/2017)... ... 10, 2017 , ... The Pittcon Program Committee is pleased ... scientists who have made outstanding contributions to analytical chemistry and applied spectroscopy. Each ... leading conference and exposition for laboratory science, which will be held February 26-March ...
(Date:10/9/2017)... ... 09, 2017 , ... At its national board meeting in North Carolina, ... University’s Departments of Physics and Astronomy, has been selected for membership in ARCS ... for the 2015 Breakthrough Prize in Fundamental physics for the discovery of the accelerating ...
Breaking Biology Technology:
(Date:3/29/2017)... , March 29, 2017  higi, the health IT ... North America , today announced a ... the acquisition of EveryMove. The new investment and acquisition ... of tools to transform population health activities through the ... data. higi collects and secures data today ...
(Date:3/27/2017)... , March 27, 2017  Catholic Health ... and Management Systems Society (HIMSS) Analytics for achieving ... Adoption Model sm . In addition, CHS previously ... U.S. hospitals using an electronic medical record (EMR). ... its high level of EMR usage in an ...
(Date:3/24/2017)... , Mar 24, 2017 Research and ... Access System Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 15.1% over the next ... This industry report analyzes the market estimates and forecasts for all ...
Breaking Biology News(10 mins):